OSR Health Shifts $15M Option to Convertible Notes

Holders of OSRH shares should expect VXM01 funding to arrive in milestone-based tranches rather than one upfront payment.

Updated on Nov. 6, 2026 in Healthcare

OSR Health Shifts $15M Option to Convertible Notes

OSR Health exercised its $15 million equity option under the VXM01 global license agreement with BCM Europe AG and elected to settle it through convertible notes rather than a cash purchase of common stock. The notes are intended to be issued to a third-party purchaser arranged by BCME, with closing targeted by December 31, 2026, affecting holders of the company's OTC Pink-listed shares (OSRH).

Why it matters

The company describes the exercise as a step toward committed, staged funding that would improve its balance sheet. Settling through convertible notes instead of a cash stock purchase means the financing depends on milestone-based tranches rather than a single upfront payment.

OSR Health exercised a $15 million equity option at $10.00 per share and elected note settlement instead. The company trades on the OTC Pink under OSRH and reports that holders of more than 51% of its outstanding shares are enrolled in its CVR Shareholder Loyalty Program.

The players

OSR Health

OSR Health is the U.S.-listed holding company whose stock trades on the OTC Pink under OSRH, with its licensed VXM01 asset developed through Vaximm AG.

BCM Europe AG

BCM Europe AG is the counterparty granting the equity option under the VXM01 global license agreement, arranging the note purchase through BCME.

The details

Under the option, the company could have sold up to $15 million of common stock to BCME at $10.00 per share, but it chose to settle through convertible notes. The company intends to issue up to $15 million principal amount of those notes to a third-party purchaser arranged by BCME, with funding expected in tranches as defined milestones are met. The VXM01 global license agreement was amended in October 2026, and the company is also pursuing OTCQB quotation, subject to OTC Markets Group approval.

Timeline

  1. October 2026: VXM01 global license agreement amended.

  2. November 6, 2026: OSR Health exercised its $15 million VXM01 equity option.

  3. December 31, 2026: Targeted closing date for the convertible note purchase.

  4. End of 2026: Vaximm AG targets publication of a VXM01 clinical data manuscript.

Market Landscape

Under the VXM01 global license agreement, as amended in October 2026, OSR Health has moved from an equity-based option to milestone-linked convertible notes. The financing structure sits alongside the company's pursuit of OTCQB quotation and a proposed reverse takeover of OSRK, a Nasdaq-listed counterparty tied to its controlling interest.

Shareholders should expect financing to arrive in milestone-based tranches rather than as a single payment, which makes timing dependent on defined clinical or corporate milestones. Holders should monitor the December 31, 2026 closing target and the ten-business-day reversion window, and consult a qualified securities attorney or accountant before acting on any position.

The takeaway

The key operating signal is that OSR Health is converting an equity option into convertible notes funded in tranches, so its near-term cash position depends on hitting defined milestones. Track whether the note purchase closes by the targeted December 31, 2026 date, and route any decision about the position to a qualified professional.

What happens next

The convertible note purchase is targeted to close no later than December 31, 2026, and the equity option reverts if it does not close within ten business days after the scheduled closing date.

Further reading

For broader context on how drug-development financing is structured, see the Healthcare section.

Source note: This article includes information reported by Hawaii Telegraph.